Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of SPN-810 for Impulsive Aggression in Pediatric ADHD
NCT02691182Phase 3Terminated
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of molindone in intermittent explosive disorder (IED), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Retrospective-Modified Overt Aggression Scale at 60 months, Clinical Global Impression - Severity at 60 months and 1 more. Started Apr 2016; status: terminated.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT02691182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691182.